Thomas G. Martin MD

Hematology•San Francisco, CA

Professor, Medicine, UCSF School of Medicine

Join to View Full Profile

400 Parnassus AveSan Francisco, CA 94143
Phone+1 415-353-2421
Fax+1 415-353-2467

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1993 - 1996
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1989 - 1992
Uconn School Of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 1991 - 2026
TX State Medical License 1999 - 2002
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer Start of enrollment: 1999 Jan 01
Completed
Not Applicable
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2002 Jan 01
Withdrawn
Phase 2
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 1
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1
Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders Start of enrollment: 1999 Jan 01
Completed
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors Start of enrollment: 2005 Aug 01
Completed
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies Start of enrollment: 2004 Aug 01
Terminated
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies Start of enrollment: 2002 Oct 01
Terminated
Not Applicable
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT Start of enrollment: 2002 Nov 01
Completed
Phase 2
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2004 Oct 01
Withdrawn
Phase 1, Phase 2
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2004 Oct 28
Terminated
Phase 1, Phase 2
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine Start of enrollment: 2010 Feb 01
Completed
Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen Start of enrollment: 2009 Nov 01
Completed
Phase 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
Join now to see all

Publications & Presentations

PubMed

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer
Blood Advances. 2025-03-15
2 citations
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal
Leukemia. 2025-03-01
1 citations
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune
Journal of Clinical Oncology. 2025-02-18

Lectures

Approaches To Achieve the Best Possible Outcomes in Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Managing Multiple Myeloma: What's Next?
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

FDA Approves New CAR T Cancer Therapy for Form of Multiple MyelomaFebruary 28th, 2022
New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (Cilta-Cel) in Treatment of Heavily Pre-Treated Patients with Multiple MyelomaDecember 12th, 2021